Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 9/20 | 0.44 |
| ▸ | MAOA | P21397 | 8/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.40 |
| ▸ | ABAT | P80404 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.40 |
| ▸ | HPD | P32754 | 2/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29800426 | 0.87 | HPD (0.45) | PTPN1MAOBMAOASMN1; SMN2ALDH5A1 | |
| SCHEMBL30318898 | 0.83 | HPD (0.49) | ALDH1A1MEN1KMT2AGPR35HPD | |
| SCHEMBL1121791 | 0.83 | HPD (0.49) | ALDH1A1MEN1KMT2AGPR35HPD | |
| SCHEMBL27765514 | 0.72 | GPR35 (0.51) | PTPN1ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL23748560 | 0.72 | CCNB2 (0.52) | ALDH1A1SMN1; SMN2MEN1KMT2AHPD | |
| SCHEMBL17560070 | 0.72 | ALDH1A1 (0.61) | MAOBMAOAALDH1A1MEN1KMT2A | |
| SCHEMBL15013285 | 0.72 | MAPT (0.55) | ALDH1A1MEN1KMT2AHPDHTR1A | |
| SCHEMBL18002426 | 0.72 | SMN1; SMN2 (0.59) | MAOBMAOAALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL29800420 | 0.71 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL18002412 | 0.70 | MRGPRX4 (0.60) | MAOBMAOAALDH1A1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188092-A1 | RIFAMYCIN ANALOGS | THE PENN STATE RESEARCH FOUNDATION | 2025-06-12 | — | — | US | disclosed |
| WO-2022159491-A1 | RIFAMYCIN ANALOGS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188092-A1 | RIFAMYCIN ANALOGS | CYP3A4, CYP4B1, CYP2C9 | PTPN1 4158/4885MAOB 1851/4885MAOA 1829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.